Although no signs of toxicity in the C57BL/6NCrl mice were observed, long-term treatment must be carefully monitored, and clinical studies are required to evaluate this promising combination and optimize the results of anti-PD1-based immunotherapy against malignant melanoma. Here, PDCD1 is linked to melanoma.